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Acute myocardial infarction (AMI) occurs when the
atheromatous process prevents total blood flow
through the coronary artery. It was previously thought
that progressive luminal narrowing from the continued
growth of smooth muscle cells (SMCs) in the plaque
was the main cause of infarction, however, angiograph-
ic studies, have identified culprit lesions that do not
cause marked stenosis.
Is now evident that plaque activation, rather than
stenosis, precipitates ischemia and infarction. Coronary
spasm could be involved to some extent, but most cas-
es of AMI are due to the formation of an occluding
thrombus on the surface of the plaque; the two major
causes of coronary thrombosis are plaque rupture and
endothelial erosion. Plaque rupture is detectable in 60-
70% of cases and preferentially occurs when the fibrous
cap is thin and partly destroyed. One of the major chal-
lenges in modern cardiology is the knowledge of the
factors that induce a silent atherosclerotic plaque shift-
ing from a stable to a vulnerable form.
The identification of blood-borne inflammatory and
immune cells inside the atheroma, led us to postulate
the involvement of an immune-inflammatory mecha-
nism in atherogenesis, from plaque formation to the in-
duction of its complication (1). Moreover, recent studies
in animal models, as well as in humans, support the hy-
pothesis that the accumulation and modification of low
density lipoprotein (LDL) in the arterial intima triggers
the innate immune system, which might be the first step
in the atherosclerosis process.  
Hypercholesterolemia causes infiltration and reten-
tion of LDL in the arterial intima (2) where it undergoes
through a progressive oxidation process leading to ox-
LDL that are internalized by macrophages and initiate
an inflammatory response in the artery wall by inducing
endothelial cell dysfunction and smooth muscle prolif-
eration. In addition, this modified LDL up-regulates the
expression of leukocyte adhesion molecules (vascular
cell adhesion molecule 1-V-CAM 1, E/P-selectin), as
well as other chemokines, such as macrophage colony-
stimulating factor (M-CSF) and monocyte chemoattrac-
tant protein-1 (MCP-1), in the endothelial cells. Through
those mechanisms, ox-LDLs expand the inflammatory
process, induce monocytes prematurely entering into
the subendothelial space and differentiating into
macrophages, and up-regulate the expression of scav-
enger receptors (SRs) and toll-like receptors (TLRs) (3,
4) on the surface of activated macrophages.
Scavenger receptors (SR-AI and AII, MARCO, CD36,
CD68, SR-PSOX) recognize the structural motif shared
by a wide variety of components including bacterial en-
dotoxins, apoptotic cells and ox-LDL; which all are tak-
en up by activated cells and are destroyed through this
pathway, nevertheless, when ox-LDL internalization ex-
ceeds their elimination by macrophages these cells
store lipids becoming foam cells. On the other hand, the
binding of oxLDL to TLRs initiate a cascade, which in-
duces cell activation through the transmission of trans-
membrane signals (5), which activate nuclear factor
kappa B (NF-κB) and mitogen activated protein kinase
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(MAPK) pathways; therefore, it induces the expression
of wide variety of genes, such as those encoding sever-
al cytokines, proteases, protein involved in leukocyte
recruitment, production of reactive oxygen species and
phagocytosis, which contribute to start and to amplify
the local inflammation.
Other than from ox-LDL, TLRs can be triggered by
heat shock protein (HSP) 60, bacterial wall components
and virus DNA or virus RNA; therefore, the atherosclero-
sis process could rely on several activating stimuli (6, 7).
T-cells participate in the formation of atherosclerotic
lesions as early as monocytes, and they play a key role
in the arm of adaptive immunity. The cells of adaptive
immunity recognize specific molecular structures ex-
posed by antigen presenting cells in the contest of MHC
determinants. The activity of those cells depends on the
generation of a large number of antigen receptors, such
as T-cell receptors (TCRs) and immunoglobulin, by so-
matic rearrangement processes in blast cells. The effec-
tor activity of the adaptive immune system includes di-
rect attack of antigen bearing cells by cytotoxic T lym-
phocytes (CTL), stimulation to B-cells to produce anti-
body against the antigen, and induction of inflamma-
tion, with enhanced innate response, in the area near
the antigen.
T-cells are always present in atherosclerotic lesions;
they predominantly are CD4+, CD3 +, TCRα/β +, T-cells,
which recognize protein antigens presented to them as
fragments bound to major histocompatibility complex
class II (MHC-II) molecules. Initial activation of “naive”
T-cells requires strong activating stimuli, best provided
by the dendritic cells, a specialized macrophage cell.
Once successful activation has occurred, the remaining
memory T-cells have a lower activation threshold; there-
fore, subsequent rounds of stimulation require a lesser
amount of antigen. Regular macrophage, not just den-
dritic cells, can accomplish this less stringent function
and reactivation can occur in non-lymphoid tissues
such as the vessel wall.
Lesional T-cells mainly have properties of the T helper
1 (Th1) subtype (8, 9) and secrete interferon-γ (IFN-γ).
IFN-γ primes macrophages, improving the efficiency of
antigen presentation and lowering the threshold for TLR
dependent activation; therefore, it increases tumor
necrosis factor-α (TNF-α) synthesis, a cardinal proin-
flammatory cytokine with NF-κB activating capacity,
and interlukin-1 (IL-1). 
In animals the extent of atherosclerosis is reduced
when the Th1 pathway is inhibited pharmacologically or
genetically (10, 11), demonstrating the key role of this
arm in the pathogenesis of the disease. Evidence from
studies in humans supports the involvement of auto-
antigens in atherosclerosis.
T-cells can be isolated from fresh human plaques,
cloned, expanded in culture, and finally challenged with
candidate antigens. Such experiments have identified
ox-LDL as a major auto-antigen in the cellular immune
response of atherosclerosis (12). This finding, together
with the detection of anti-ox-LDL antibodies in athero-
sclerotic patients and experimental animals (13), sup-
ports the concept that immune responses to ox-LDL
operate in atheroma.
Several studies have linked infection to atherosclero-
sis and coronary artery disease (CAD). Although many
questions are unanswered, it has been shown that
pathogens can trigger the innate immunity by binding
TLRs and could activate the adaptive immune respons-
es through several mechanisms including the molecular
mimicry, direct T-cell activation and autoimmune reac-
tions; moreover, the infectious agents can affect the
vascular biology through the direct infection of tissue.
Based on this, it has been proposed that chlamydia
pneumoniae and cytomegalovirus in atherogenesis can
play a role in the atherosclerosis pathology (14-25). 
Further antigens involved in atherosclerosis are heat
shock proteins 60 and 65 (HSP60-65), a protein pro-
duced in large amounts by injured cells, which act as
“chaperones” to limit denaturation of other cellular pro-
teins. HSP60 release can not only induce specific anti-
bodies and T-cells, but also directly activate innate im-
munity, binding TLR-4 receptors like a bacterial endo-
toxin (26, 27).
Cytokines produced by Th1 cells and macrophages
produce large amounts of molecules downstream in the
cytokine cascade. As a result, elevated levels of IL-1,
IL-6, TNF-α, IFN-γ, and C-reactive protein (CRP) can be
detected in the peripheral circulation, with high levels
predicting worse prognosis. In this way, the activation
of a limited number of immune cells can initiate a cas-
cade, both in the forming lesion and systemically.
Elevated CRP levels in patients with acute coronary
syndrome likely reflects this inflammatory activity in the
coronary artery, rather than in ischemic myocardium
(28); this finding suggests that inflammatory immuneVercellino et al
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activation in the coronary arteries initiates acute coro-
nary syndromes, with circulating levels of inflammatory
markers reflecting the clinical course of the condition. 
The central lipid-rich core of the typical atheroscle-
rotic lesion contains many lipid-laden macrophage
foam cells that produce large amounts of tissue factor
(TF), an extremely potent pro-coagulant, which can
stimulate thrombus formation when in contact with
blood (29). Therefore, coronary thromboses result fre-
quently from a fracture in the protective fibrous cap.
Ample evidence now supports the concept that the
protective fibrous cap, far from being fixed and static,
actually can undergo continuous and dynamic remod-
eling and displays considerable metabolic activity
(30).
The balance between synthetic and degradative
processes, closely controlled by inflammation media-
tors, regulates the collagen level in this structure; for
example, the above-mentioned lymphokine INF-γ, can
inhibit de novo synthesis of interstitial collagen by
SMCs (31). Moreover, proinflammatory cytokines in-
duce the expression of enzymes, capable of breaking
down constituents of the arterial extracellular matrix
(ECM); in particular, matrix metalloproteinases (MMP)
can degrade the collagen fibrils that lend strength to
the plaque’s fibrous cap (32, 33).
SMCs also influence the levels of ECM, by the pro-
duction of major isoforms of tissue inhibitors of metal-
loproteinases (TIMPs) (34).  Fatal thrombosis sites
typically have few SMCs (35, 36), since inflammatory
stimuli can trigger the apoptosis of these cells (37).
As we have seen above, fatal thrombosis in coro-
nary arteries occasionally results from the erosion of
the endothelial cells, which uncovers the thrombo-
genic subendothelial matrix (38, 39). Inflammation can
contribute to this mechanism, inducing the endothe-
lial cells apoptosis (40, 41) and increasing the expres-
sion of TF and PAI-1 (42). 
Vasospasm reducing the arterial flow can also con-
tribute to increasing hypoxia that precipitates the en-
dothelium dysfunction leading to the reduced produc-
tion of vasodilatative factors (PG, and nitric oxide)
and the increase of vasoactive substances like en-
dothelins and tromboxane. Consequent to inflamma-
tory stimuli, endothelial cells in atherosclerotic arter-
ies show impaired vasodilator function, in part from
the decreased production of nitric oxide while the va-
sospasm is increased as well as the thrombophylic
state. In addition to producing vasodilatation, nitric
oxide can weaken platelet aggregation and has a di-
rect anti-inflammatory effect; moreover, augmenting
the production of the inhibitor of NF-κB the inflamma-
tion results to be activated (43-45).
The above-reported elements, strongly suggest
that atherosclerosis can be considered as an autoim-
mune or an immuno-mediated disease characterized
by the imbalance among regulatory and effector
mechanisms of the immune system.
The immunologic homeostasis is achieved by a
physiological mechanism (peripheral immune toler-
ance) aimed at containing the peripheral immune sys-
tem from damaging tissues by excessive reactivity
and/or preventing auto-reactive T-cells, which have
escaped the thymus negative selection, from causing
autoimmunity.
The peripheral immune tolerance is quite a complex
situation that can be achieved through several mech-
anisms that include ignorance, anergy, apoptosis, ex-
haustion, immune deviation and suppression. There-
after, it seems logical, given the above-mentioned
findings, to suggest that impairment in maintaining
tolerance could contribute to the onset of atheroscle-
rotic disease.
Looking at this context, it is of interest to underline
that atheroma lesions contain a large number of Th1
cells in contrast with the only modest quantitative of
Th2 cells. Since Th2 cells, at variance of the Th1
counterpart, secrete a set of cytokines (IL-4, IL-10, tu-
mor growth factor-β (TGF-β)) performing immunosup-
pressive activity, one can hypothesize that Th2 cells
could be protective against atherosclerosis.
Th1 activated cells facilitate atherogenesis and
produce cytokines, such as IL-12 and IL-18, which
stimulate their own proliferation and inhibit the Th2 re-
sponse (46-52). In contrast, IL-4 and IL-10, produced
by Th2, may inhibit Th1 activity and the development
of vascular disease. This hypothesis seems to be con-
firmed by some experimental evidence that shows
that IL-10 gene targeting, as well as its pharmacolog-
ic inhibition, aggravates atherosclerosis in hypercho-
lesterolemic mice and exacerbates coronary throm-
bosis (53-55). Moreover, abrogation of TGF-β signal-
ing in T-cells, elicits a dramatic phenotype, with rapid
development of large, unstable atherosclerotic plaquesThe immune system in atherosclerosis and in acute myocardial infarction
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(56). These findings indicate that immunity is under
tonic inhibition, by TGF-β and IL-10, and that the re-
moval of these brakes on the effector T lymphocytes
accelerates the atherosclerosis process.
The antibody producing B-cell harm seems to be
less involved in the atherosclerotic disease; few B lym-
phocytes are detectable in the lesions. In our experi-
ence, in humans, we found low circulating levels of IgG
specific for ox-LDL in the serum of patients affected by
AMI (57). Nevertheless, several reports suggest that B
lymphocytes could exert a protective activity in the
atherosclerosis diseases through different mecha-
nisms.
First, IgG could bind and inactivate the ox-LDL anti-
gen, which represents a chronic immunological stress
for the plaque. 
Secondly, the low circulating levels of IgG to ox-LDL
in AMI could depend on extreme activation of the Th1
arm in the vascular lesions (see above concerning
cross regulation between Th1/Th2). 
Finally, it could be an indirect marker of the reduced
activity of some protective cells, like B lymphocytes,
whose activation is under the control of Th2 pathway.
Is not definitely known whether such athero-protec-
tive effects depend on circulating antibodies against
plaque antigens or on T-B cells interaction mediated
by cytokines, however, several studies lead us to pre-
fer the first hypothesis.
Immunization in animals with ox-LDL reduces ather-
osclerosis in hypercholesterolemic rabbit and mice,
and the transfer of immunoglobulins also inhibits dis-
ease development (58-61). Spleen B-cells, which are
particularly effective atherosclerosis inhibitors, recog-
nize phosphorylcholine, a molecule present in ox-LDL,
apoptotic cell membranes and in the wall of Strepto-
coccus pneumoniae (62, 63).
These antibodies may contribute to the elimination
of ox-LDL and dead cells, as well as to the defence
against pneumococcal infection; interestingly, patients
who have undergone splenectomy, have increased
susceptibility, not only to pneumococcal infection, but
also to CAD (64). 
Knowledge regarding the role of immunity and in-
flammation in CAD provides new insights into the
pathogenesis of CAD, of acute coronary syndrome and
particularly of myocardial infarction; moreover, it offers
new opportunities in the diagnosis, prediction and
treatment of this life threatening disease.
Immunosuppressant or anti-inflammatory agents
could represent attractive treatments for acute coro-
nary syndrome. Cyclosporine, syrolimus and tacro-
limus block the activation and proliferation of T-cells,
as well as of SMCs; although they are actually em-
ployed in drug eluting stents to prevent restenosis, we
still do not know whether this compound family could
be used systemically in the prevention and treatment
of acute coronary syndrome (65-67). Moreover, the
“late thrombosis” of drug eluting stents has taught
physicians that the inhibition of immune-inflammatory
system may be dangerous, particularly if it is not
aimed at a specific target.
Equally complex is the situation of anti-inflammato-
ry drugs; recent data showed increased incidence of
cardiovascular events in patients treated with rofe-
coxib, a cycloxigenase-2 inhibitor which blocks the
production of the anti-thrombotic compound by
platelets (68).
Statins are certainly the best usable anti-inflamma-
tory drug in clinical practice (69-77) this pleiotropic ef-
fect depends on the inhibition of isoprenoid intermedi-
ate and cholesterol production by mevalonic acid.
Isoprenoids control the activity of many signaling
pathways; reduced cholesterol synthesis may interfere
with the membrane composition and with the cluster-
ing of T-cell receptors during immune activation.
Therefore, statins may inhibit antigen-dependent T-cell
activation. The vaccine represents an attractive ap-
proach, because it could conversely induce a protec-
tive immunity (78) against a specific target. In animals,
atherosclerosis was reduced by vaccination with ox-
LDL or HSP60 (58, 61, 79-81) this could be due to the
induction of protective auto-antibodies or T-cells. 
Since better antigen preparation must be developed
and more knowledge obtained before the vaccination
can be tested in humans, several research groups are
trying to identify the molecular properties of antigens,
which may cause an immune response in atheroscle-
rotic lesions.
Other perspectives have come from research re-
garding inflammatory cytokines; some of these com-
pounds, especially TGF-β, regulate the immune re-
sponse by the inhibition of T-cells, and so it looks very
promising for the future management of atheroscle-
rotic disease.Vercellino et al
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